Literature DB >> 21892652

BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231.

Ke Wang1, Honglei Feng, Wei Ren, Xiaoxiao Sun, Jinyong Luo, Min Tang, Lan Zhou, Yaguang Weng, Tong-Chuan He, Yan Zhang.   

Abstract

BACKGROUND: Transforming growth factor-β (TGF-β) is known to promote tumor proliferation, migration, invasion, and metastasis. Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily. Several BMPs (BMP2 and BMP7) can enhance the invasion and bone metastasis of breast cancer cells. The function of BMP9, the latest discovered and most powerful osteogenetic factor, in breast cancer has not been fully elucidated.
METHODS: BMP9 expression in twenty-three breast cancer patients and three breast cancer cell line types was detected by reverse transcriptase polymerase chain reaction. Changes in proliferation, apoptosis, invasion, and migration in the recombinant MDA-MB-231/BMP9 cells were detected using various assays. The assays were MTT, flow cytometry, colony forming, cell wounding, and transwell invasion. Proliferating cell nuclear antigen and terminal deoxynucleotidy transferase biotin-dUTP nick end labeling staining methods were conducted to detect whether BMP9 affected proliferation and apoptosis in xenogenic mouse models.
RESULTS: Twenty-one of the twenty-three breast cancer patients had amplified BMP9 mRNA transcripts in adjacent non-tumor tissues, although BMP9 was observed in the breast cancer tissue of two patients, its expression was higher in the adjacent non-tumor tissues. BMP9 overexpression inhibited the proliferation, migration, and invasion, as well as induced the apoptosis of the breast cancer cell line MDA-MB-231 in vitro. BMP9 also inhibited tumor growth and induced apoptosis significantly in the xenogenic mouse models.
CONCLUSIONS: Decreased BMP9 expression is associated with the elevated proliferation and migration of human breast cancer. BMP9 can inhibit the growth, invasion, and migration of breast cancer cells in vitro and in vivo. BMP9 is a putative tumor suppressor in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21892652     DOI: 10.1007/s00432-011-1047-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs).

Authors:  Hongwei Cheng; Wei Jiang; Frank M Phillips; Rex C Haydon; Ying Peng; Lan Zhou; Hue H Luu; Naili An; Benjamin Breyer; Pantila Vanichakarn; Jan Paul Szatkowski; Jae Yoon Park; Tong-Chuan He
Journal:  J Bone Joint Surg Am       Date:  2003-08       Impact factor: 5.284

Review 2.  BMP signaling in vascular development and disease.

Authors:  Jonathan W Lowery; Mark P de Caestecker
Journal:  Cytokine Growth Factor Rev       Date:  2010-07-31       Impact factor: 7.638

3.  BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1.

Authors:  M K Majumdar; E Wang; E A Morris
Journal:  J Cell Physiol       Date:  2001-12       Impact factor: 6.384

Review 4.  Specificity and versatility in tgf-beta signaling through Smads.

Authors:  Xin-Hua Feng; Rik Derynck
Journal:  Annu Rev Cell Dev Biol       Date:  2005       Impact factor: 13.827

5.  Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation.

Authors:  Blanca Herrera; Maarten van Dinther; Peter Ten Dijke; Gareth J Inman
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

6.  Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways.

Authors:  Jun Du; Shuang Yang; Zhaoqi Wang; Chunli Zhai; Wei Yuan; Rongyue Lei; Jie Zhang; Tianhui Zhu
Journal:  J Cell Biochem       Date:  2008-04-01       Impact factor: 4.429

7.  Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway.

Authors:  Y Katsuno; A Hanyu; H Kanda; Y Ishikawa; F Akiyama; T Iwase; E Ogata; S Ehata; K Miyazono; T Imamura
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

8.  BMP7 influences proliferation, migration, and invasion of breast cancer cells.

Authors:  Emma-Leena Alarmo; Jenita Pärssinen; Johanna M Ketolainen; Kimmo Savinainen; Ritva Karhu; Anne Kallioniemi
Journal:  Cancer Lett       Date:  2008-11-05       Impact factor: 8.679

9.  Expression of bone morphogenetic protein in human adenocarcinoma cell line.

Authors:  S Hatakeyama; Y Ohara-Nemoto; S Kyakumoto; M Satoh
Journal:  Biochem Biophys Res Commun       Date:  1993-02-15       Impact factor: 3.575

10.  Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.

Authors:  Lin Ye; Howard Kynaston; Wen G Jiang
Journal:  Mol Cancer Res       Date:  2008-10       Impact factor: 5.852

View more
  25 in total

1.  Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion.

Authors:  Zilan Lv; Dandan Yang; Jie Li; Min Hu; Min Luo; Xiaoqin Zhan; Peipei Song; Chen Liu; Huili Bai; Baolin Li; Yang Yang; Yingying Chen; Qiong Shi; Yaguang Weng
Journal:  Mol Cells       Date:  2013-06-25       Impact factor: 5.034

2.  BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression.

Authors:  Wei Ren; Xiaoxiao Sun; Ke Wang; Honglei Feng; Yuehong Liu; Chang Fei; Shaoheng Wan; Wei Wang; Jinyong Luo; Qiong Shi; Min Tang; Guowei Zuo; Yaguang Weng; Tongchuan He; Yan Zhang
Journal:  Mol Biol Rep       Date:  2014-01-12       Impact factor: 2.316

3.  Impact of selective anti-BMP9 treatment on tumor cells and tumor angiogenesis.

Authors: 
Journal:  Mol Oncol       Date:  2016-12       Impact factor: 6.603

4.  BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma.

Authors:  Elena Porcù; Francesca Maule; Daniele Boso; Elena Rampazzo; Vito Barbieri; Gaia Zuccolotto; Antonio Rosato; Chiara Frasson; Giampietro Viola; Alessandro Della Puppa; Giuseppe Basso; Luca Persano
Journal:  Cell Death Differ       Date:  2018-07-05       Impact factor: 15.828

5.  BMP-binding protein twisted gastrulation is required in mammary gland epithelium for normal ductal elongation and myoepithelial compartmentalization.

Authors:  Cynthia L Forsman; Brandon C Ng; Rachel K Heinze; Claire Kuo; Consolato Sergi; Rajaram Gopalakrishnan; Douglas Yee; Daniel Graf; Kathryn L Schwertfeger; Anna Petryk
Journal:  Dev Biol       Date:  2012-10-24       Impact factor: 3.582

6.  BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells.

Authors:  Shaoheng Wan; Yuehong Liu; Yaguang Weng; Wei Wang; Wei Ren; Chang Fei; Yingying Chen; Zhihui Zhang; Ting Wang; Jinshu Wang; Yayun Jiang; Lan Zhou; Tongchuan He; Yan Zhang
Journal:  Cell Oncol (Dordr)       Date:  2014-09-11       Impact factor: 6.730

7.  Biological roles of human bone morphogenetic protein 9 in the bone microenvironment of human breast cancer MDA-MB-231 cells.

Authors:  Wei Wang; Yaguang Weng; Wei Ren; Zhihui Zhang; Ting Wang; Jinshu Wang; Yayun Jiang; Yingying Chen; Lan Zhou; Tongchuan He; Yan Zhang
Journal:  Am J Transl Res       Date:  2015-09-15       Impact factor: 4.060

8.  RGS5-TGFβ-Smad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth.

Authors:  Shayani Dasgupta; Tithi Ghosh; Jesmita Dhar; Avishek Bhuniya; Partha Nandi; Arnab Das; Akata Saha; Juhina Das; Ipsita Guha; Saptak Banerjee; Mohona Chakravarti; Partha Sarathi Dasgupta; Neyaz Alam; Jayanta Chakrabarti; Subrata Majumdar; Pinak Chakrabarti; Walter J Storkus; Rathindranath Baral; Anamika Bose
Journal:  Cell Death Differ       Date:  2021-05-19       Impact factor: 12.067

9.  Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß.

Authors:  Isabel M Chu; Wei-Chu Lai; Olga Aprelikova; Lara H El Touny; Hosein Kouros-Mehr; Jeffrey E Green
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

Review 10.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.

Authors:  Stephan Herbertz; J Scott Sawyer; Anja J Stauber; Ivelina Gueorguieva; Kyla E Driscoll; Shawn T Estrem; Ann L Cleverly; Durisala Desaiah; Susan C Guba; Karim A Benhadji; Christopher A Slapak; Michael M Lahn
Journal:  Drug Des Devel Ther       Date:  2015-08-10       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.